SynthesisInternational journal of hematology2025
Sarcopenia and clinical outcomes in lymphoma and multiple myeloma patients receiving hematopoietic cell transplantation: a systematic review and meta-analysis.
Synthesis in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Psoas and pectoralis muscle indices and brown adipose tissue activity may be prognostic indicators in older patients with multiple myeloma.International journal of hematology · 2026Article
- Review
- The impact of sarcopenia and body mass index on treatment toxicity and survival in patients with extranodal natural killer/T-cell lymphoma: a retrospective analysis.Frontiers in oncology · 2026Article
- The Evolving Treatment Landscape for the Elderly Multiple Myeloma Patient: From Quad Regimens to T-Cell Engagers and CAR-T.Cancers · 2025Review
- Circulatory cathepsin K as biomarkers in older adults with sarcopenia: a case-control study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia, characterized by skeletal muscle loss, is increasingly recognized as a predictor of poor outcomes in hematologic malignancies. This study evaluated the impact of sarcopenia on survival and post-transplant outcomes in lymphoma and multiple myeloma patients undergoing hematopoietic cell transplantation (HCT).
methodsA systematic review of eleven retrospective studies (2015-2024) including 1866 patients was conducted. Sarcopenia was assessed by CT, with some variation in diagnostic criteria. Pooled analyses were conducted to examine associations with mortality, progression-free survival (PFS), and non-relapse mortality (NRM).
resultsThe overall prevalence of sarcopenia was 45.7% (lymphoma: 44.2%, multiple myeloma: 49%). Sarcopenia significantly increased mortality risk in lymphoma (HR 1.92, 95% CI 1.61-2.29, p < 0.00001) and multiple myeloma patients (HR 1.12, 95% CI 1.03-1.22, p = 0.01). PFS was worse in lymphoma patients (HR 2.40, 95% CI 1.44-4.36, p = 0.0009), but NRM did not differ significantly.
conclusionSarcopenia is a significant risk factor for poor outcomes in HCT recipients. Routine assessment and targeted interventions, including nutritional and exercise strategies, may improve patient outcomes. Further prospective studies are needed to establish standardized diagnostic criteria and explore therapeutic interventions.
Indexed as
Identifiers
40358877What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.